Evidence map›Paper›PMID 40283967›Full record

ReviewPharmaceuticals (Basel, Switzerland)2025

An Overview of the Effects of Lithium on Alzheimer's Disease: A Historical Perspective.

Marcia Radanovic, Monique Patricio Singulani, Vanessa de Jesus R De Paula, Leda Leme Talib, Orestes Vicente Forlenza

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marcia RadanovicLaboratory of Neuroscience (LIM-27), Department and Institute of Psychiatry, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo 05403-010, SP, Brazil.ORCID 0000-0002-3256-6397
Monique Patricio SingulaniLaboratory of Neuroscience (LIM-27), Department and Institute of Psychiatry, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo 05403-010, SP, Brazil.ORCID 0000-0001-7019-0485
Vanessa de Jesus R De PaulaLaboratory of Neuroscience (LIM-27), Department and Institute of Psychiatry, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo 05403-010, SP, Brazil.ORCID 0000-0002-2054-6356
Leda Leme TalibLaboratory of Neuroscience (LIM-27), Department and Institute of Psychiatry, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo 05403-010, SP, Brazil.ORCID 0000-0001-5866-1993
Orestes Vicente ForlenzaLaboratory of Neuroscience (LIM-27), Department and Institute of Psychiatry, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo 05403-010, SP, Brazil.ORCID 0000-0002-6962-5899

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lithium was introduced into psychiatric practice in the late nineteenth century and has since become a standard treatment for severe psychiatric disorders, particularly those characterized by psychotic agitation. It remains the most effective agent for managing acute mania and preventing relapses in bipolar disorder. Despite potential adverse effects, lithium's use should be carefully considered relative to other treatment options, as these alternatives may present distinct safety and tolerability profiles. The World Health Organization classifies lithium salts as 'essential' medications for inclusion in global healthcare systems. Over the past two decades, the growing recognition of lithium's efficacy-extending beyond mood stabilization to include reducing suicide risk and inducing neuroprotection-has led to its incorporation into clinical practice guidelines. Current research, particularly from translational models, suggests that lithium's pleiotropic effects benefit not only mental and brain health but also other organs and systems. This supports its potential as a therapeutic candidate for neurological conditions, particularly those associated with neurodegenerative processes. This article will discuss the historical background, discovery, and early experimentation of lithium in psychiatry. We will also review its mechanisms of action and discuss its potential in the treatment and prevention of neurodegenerative disorders, focusing on Alzheimer's disease.

Indexed as

Alzheimer’s diseaselithium saltslithium therapyneurodegenerative diseasesneuroprotection

Identifiers

PMID40283967
PMCPMC12030194

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.